Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:
Pursuant to the article L. 233-8 II of the French 'Code de Commerce' and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or ' AMF ') General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') releases its total number of shares outstanding as well as its voting rights as at April 25, 2025:
(1) The total number of theoretical voting rights (or 'gross' voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.
(2) The total number of exercisable voting rights (or 'net' voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform, Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'expect' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Jim Cramer Highlights That Dollar Tree (DLTR) Has 'More Trouble With the Tariffs'
We recently published a list of . In this article, we are going to take a look at where Dollar Tree, Inc. (NASDAQ:DLTR) stands against other stocks that Jim Cramer discusses. Discussing the impact of tariffs on Dollar Tree, Inc. (NASDAQ:DLTR), Cramer stated: 'Discount retailers tend to do better when the consumers' feeling stretched thin, and you know the consumer's feeling that way. But Dollar General and Dollar Tree have behaved very differently after reporting earnings over the past couple days… Then today, Dollar Tree reported what I also thought was a pretty good quarter, but its stock got eviscerated, down 8%. What explains the disparity here?… The difference between these two comes down to what they had to say about their ability to control costs and offset the impact of, you bet, go ahead, the president's tariffs… A shopper browsing through a discount retailers merchandise aisle filled with a wide variety of items. Dollar Tree (NASDAQ:DLTR) runs discount retail stores that carry a wide variety of products. The selection includes consumables, home essentials, seasonal items, apparel, and electronics. Overall, DLTR ranks 8th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of DLTR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Was Jim Cramer Right About Meta Platforms, Inc. (META)?
We recently published a list of . In this article, we are going to take a look at where Meta Platforms, Inc. (NASDAQ:META) stands against other stocks that Jim Cramer discusses. A viewer asked if Meta Platforms, Inc. (NASDAQ:META) still had technological upside, particularly under CEO Mark Zuckerberg's leadership. In that older segment, Cramer expressed strong long-term optimism, suggesting Meta was investing in something bigger than the public could yet see. He responded with: 'I think there is. I mean, I think that they're going to be in competition in something we don't know yet. They're buying too many of the Nvidia cards for me to think they're just going to continue to be just Instagram and Facebook and WhatsApp. I think there's much more in store for us and I think you got to stay long that stock. It is not an expensive stock.' Cramer was right to call it an inexpensive stock. It's now up +39.66% since those comments. Meta Platforms, Inc. (NASDAQ:META) is a technology company that owns Facebook, Instagram, and WhatsApp, and is investing heavily in AI and virtual reality platforms like the Metaverse. When asked about the stock again recently, Cramer gave his blessing to buy it, saying: 'I like your thinking very much. I think Meta's having a great quarter. I also think that they are without a doubt the best advertising bet. What happens if he actually starts, Mark Zuckerberg starts to want to, let's say, monetize WhatsApp? Do you know how much that darn thing's worth? I think you got horse sense. Good level to buy.' A team of developers working in unison to create the company's messaging application. Overall, META ranks 6th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of META as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23 minutes ago
- Yahoo
Informa TechTarget Announces Partnership with Outreach to Help Companies Build and Accelerate Sales Pipeline Through More Intelligent Prospecting
This powerful combination helps mutual customers drive better business outcomes by efficiently identifying and effectively engaging prospects in an active buying journey NEWTON, Mass., June 09, 2025--(BUSINESS WIRE)--TechTarget, Inc. ("Informa TechTarget") (Nasdaq: TTGT), global growth accelerator and leading provider of intent data and insights to the B2B technology sector, today announced a strategic partnership and integration with Outreach, the only workflow-first sales execution platform. The integration empowers mutual customers to connect the dots between active buyer research and sales engagement so they can book more meetings, drive better conversations, create more pipeline, and accelerate deal velocity. "Roughly 9 out of 10 initial conversations with BDRs never progress through the sales cycle. Our new integration addresses this challenge head-on by fueling the timely and relevant engagement required to maximize conversion and pipeline impact," said Jillian Coffin, Senior Vice President of Customer Enablement and Strategy, Informa TechTarget. "By automatically adding Informa TechTarget's Active Prospects directly into topically aligned Outreach sequences, reps can dramatically improve their ability to connect with warm contacts when they're actively researching relevant topics and solutions." The new integration empowers sales teams to: Streamline workflows between Priority Engine, Informa TechTarget's proprietary purchase intent data platform, and Outreach to maximize sales efficiency Instantly add Active Prospects directly into relevant Outreach sequences with one click Automatically export Active Prospects to topically aligned Outreach sequences on a weekly basis Key benefits of this strategic partnership include: Increased efficiency and improved focus: Informa TechTarget's precise, person-level intent data helps reps more quickly identify and prioritize prospects with demonstrated solution interest so they can focus their efforts squarely on accounts and prospects showing active buying behavior. Timely engagement: Informa TechTarget continuously identifies new prospects from in-market accounts who are actively researching relevant topics across our network and delivers these permissioned buyers directly to Outreach. These automated workflows improve success by reducing the time to get from intent signal to outreach, enabling reps to engage prospects while they are actively researching and get into deals earlier. Improved conversion: Informa TechTarget delivers deep, real-time insights into the specific needs, pain points, and current topics of interest for each individual buyer who is actively researching on their topically relevant editorial communities. With this contextual intelligence at their fingertips, sellers can personalize every touchpoint based on a prospect's demonstrated interests and drive meaningful conversations that increase conversion to opportunity. The Informa TechTarget-Outreach integration is available now to current Priority Engine Sales subscribers at no additional cost. Customers must have both a Priority Engine Sales subscription and an Outreach license to utilize the integration. To learn more, click here. About Informa TechTarget TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI. With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market. Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients: Trusted information that shapes the industry and informs investment Intelligence and advice that guides and influences strategy Advertising that grows reputation and establishes thought leadership Custom content that engages and prompts action Intent and demand generation that more precisely targets and converts Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit and follow us on LinkedIn. © 2025 TechTarget, Inc d/b/a Informa TechTarget. All rights reserved. All trademarks are the property of their respective owners. View source version on Contacts Garrett MannVice President of Corporate CommunicationsInforma Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
